BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 10413303)

  • 1. Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells.
    Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
    Biochem Pharmacol; 1999 Aug; 58(4):655-64. PubMed ID: 10413303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA; Greene K; Ahmad S; Vistica DT
    Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.
    Anderson CP; Tsai J; Chan W; Park CK; Tian L; Lui RM; Forman HJ; Reynolds CP
    Eur J Cancer; 1997 Oct; 33(12):2016-9. PubMed ID: 9516845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.
    Tagde A; Singh H; Kang MH; Reynolds CP
    Blood Cancer J; 2014 Jul; 4(7):e229. PubMed ID: 25036800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP; Reynolds CP
    Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery.
    Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
    Cancer Chemother Pharmacol; 1999; 44(2):111-6. PubMed ID: 10412944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
    Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
    J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
    J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation.
    Troyano A; Fernández C; Sancho P; de Blas E; Aller P
    J Biol Chem; 2001 Dec; 276(50):47107-15. PubMed ID: 11602574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
    Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
    Papadopoulou MV; Ji M; Khan SH; Bloomer WD
    Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A; Pellati A; De Mattei M; De Terlizzi F; Rossi CR; Campana LG
    Anticancer Drugs; 2015 Mar; 26(3):284-92. PubMed ID: 25514113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
    J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
    Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
    Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.
    Alaoui-Jamali MA; Panasci L; Centurioni GM; Schecter R; Lehnert S; Batist G
    Cancer Chemother Pharmacol; 1992; 30(5):341-7. PubMed ID: 1505071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced thiol content in L1210 cells treated with BSO increases DNA crosslinking by melphalan.
    Dorr RT
    Biochem Biophys Res Commun; 1987 Apr; 144(1):47-52. PubMed ID: 3579919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.
    Anderson CP; Keshelava N; Satake N; Meek WH; Reynolds CP
    Med Pediatr Oncol; 2000 Dec; 35(6):659-62. PubMed ID: 11107141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line.
    Armstrong JS; Steinauer KK; Hornung B; Irish JM; Lecane P; Birrell GW; Peehl DM; Knox SJ
    Cell Death Differ; 2002 Mar; 9(3):252-63. PubMed ID: 11859408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
    Dorr RT; Liddil JD; Soble MJ
    Invest New Drugs; 1986; 4(4):305-13. PubMed ID: 3583642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.